Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors
When treated with M701, patients with MA had significantly longer puncture intervals and a trend of extended survival time. The results were encouraging for patients with MA. A phase III clinical trial of M701 aimed at further validation is ongoing.
Authors
- Fang Su (ORCID: https://orcid.org/0000-0002-4902-5191)
- Huiting Xu (ORCID: https://orcid.org/0009-0003-8314-9475)
- Zhenghong Xiao
- Yanhong Deng (ORCID: https://orcid.org/0000-0001-6873-8026)
- Rongbo Lin (ORCID: https://orcid.org/0000-0002-6877-1691)
- Yu Kang (ORCID: https://orcid.org/0000-0003-1197-4727)
- Rongrui Liu (ORCID: https://orcid.org/0000-0002-7735-7425)
- Hanxiang An (ORCID: https://orcid.org/0000-0002-8277-9526)
- Xiaojun Xiang (ORCID: https://orcid.org/0000-0002-8734-584X)
- Wei Duan (ORCID: https://orcid.org/0009-0008-2873-6163)
- Yuxian Bai (ORCID: https://orcid.org/0000-0002-5004-7523)
- Shan Zeng (ORCID: https://orcid.org/0000-0002-0988-723X)
- Qing Chen (ORCID: https://orcid.org/0000-0002-3190-8279)
- Meili Sun (ORCID: https://orcid.org/0000-0002-4914-6508)
- Ning Li (ORCID: https://orcid.org/0000-0002-8388-5080)
- Tao Zhang (ORCID: https://orcid.org/0000-0003-0692-5189)
- Yongqiang Li (ORCID: https://orcid.org/0000-0003-2871-9546)
- Jun Zhao (ORCID: https://orcid.org/0000-0002-8094-9229)
- Guiling Li (ORCID: https://orcid.org/0000-0002-0940-6010)
- Ke Wang (ORCID: https://orcid.org/0000-0002-5615-0847)
- Mingjun Zhang (ORCID: https://orcid.org/0000-0003-2337-1560)
- XU Jian-ming
- Jingdong Zhang (ORCID: https://orcid.org/0000-0002-8370-9730)
- Qi Xu (ORCID: https://orcid.org/0000-0001-9294-1956)
- Pengfei Zhou (ORCID: https://orcid.org/0000-0003-2181-3804)
- Jing Zhang (ORCID: https://orcid.org/0000-0002-0137-6902)
- Hongying Yang (ORCID: https://orcid.org/0000-0003-0246-2797)
- Fei Yin (ORCID: https://orcid.org/0000-0003-2430-9267)
- He Tian (ORCID: https://orcid.org/0000-0001-8105-9773)
- Nong Xu (ORCID: https://orcid.org/0000-0001-7499-0383)
- Weijie Zhang (ORCID: https://orcid.org/0000-0001-8382-722X)
- Shaoyi Huang
Institutions
- Hebei Medical University (CN)
- Central South University (CN)
- Nanchang University (CN)
- Harbin Medical University (CN)
- Sun Yat-sen University (CN)
- Guangxi Medical University (CN)
- Shanxi Medical University (CN)
- Anhui Medical University (CN)
- Changzhi Medical College (CN)
- Kunming Medical University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Chinese PLA General Hospital (CN)
- First Affiliated Hospital of Xiamen University (CN)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- Shandong Tumor Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Jinan Central Hospital (CN)
- Nanyang Institute of Technology (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Henan Cancer Hospital (CN)
- Obstetrics and Gynecology Hospital of Fudan University (CN)
- Fujian Provincial Cancer Hospital (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
- Wuhan YZY Biopharma (China) (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Shanxi Academy of Medical Sciences (CN)
- Xiangya Hospital Central South University (CN)
- Hubei Cancer Hospital (CN)
- Liaoning Cancer Hospital & Institute (CN)
- Shandong First Medical University (CN)
- Union Hospital (CN)
- Beijing Obstetrics and Gynecology Hospital (CN)
- First Affiliated Hospital of Nanchang University (CN)
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1186/s40164-025-00727-3
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00